|
Precocious Puberty
|
0.020 |
Biomarker
|
disease |
BEFREE |
Three boys, with precocious sexual development at 1 to 4 years of age, had low basal plasma gonadotropin values without pubertal-type pulsatility and a minimal rise in luteinizing hormone after acute stimulation with luteinizing hormone releasing factor or its potent analog D-Trp6-Pro9-NEt-LRF, distinguishing them from boys with true precocious puberty.
|
3917500 |
1985 |
|
Central Precocious Puberty
|
0.010 |
Biomarker
|
disease |
BEFREE |
Three boys, with precocious sexual development at 1 to 4 years of age, had low basal plasma gonadotropin values without pubertal-type pulsatility and a minimal rise in luteinizing hormone after acute stimulation with luteinizing hormone releasing factor or its potent analog D-Trp6-Pro9-NEt-LRF, distinguishing them from boys with true precocious puberty.
|
3917500 |
1985 |
|
Precocious Puberty
|
0.020 |
Biomarker
|
disease |
BEFREE |
These events appear to be nongonadotropin-dependent in view of the absence of a pubertal pattern of pulsatile LH secretion, persistence of a prepubertal LH response to LRF even after long standing sexual precocity, prepubertal basal levels of LH and undetectable hCG, and the absence of biologically active LH-hCG by bioassay.
|
6223935 |
1983 |
|
Cryptogenic sexual precocity
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
These events appear to be nongonadotropin-dependent in view of the absence of a pubertal pattern of pulsatile LH secretion, persistence of a prepubertal LH response to LRF even after long standing sexual precocity, prepubertal basal levels of LH and undetectable hCG, and the absence of biologically active LH-hCG by bioassay.
|
6223935 |
1983 |
|
leukemia
|
0.020 |
Biomarker
|
disease |
BEFREE |
Monosomy 20 was found in 59/2790 patients with successful karyotypes entered to the Leukaemia Research Fund/UK Cancer Cytogenetics Group Karyotype Database in ALL (LRF/UKCCG Karyotype Database).
|
10673740 |
2000 |
|
Acute lymphocytic leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Monosomy 20 was found in 59/2790 patients with successful karyotypes entered to the Leukaemia Research Fund/UK Cancer Cytogenetics Group Karyotype Database in ALL (LRF/UKCCG Karyotype Database).
|
10673740 |
2000 |
|
Childhood Acute Lymphoblastic Leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Monosomy 20 was found in 59/2790 patients with successful karyotypes entered to the Leukaemia Research Fund/UK Cancer Cytogenetics Group Karyotype Database in ALL (LRF/UKCCG Karyotype Database).
|
10673740 |
2000 |
|
Monosomy
|
0.010 |
Biomarker
|
group |
BEFREE |
Monosomy 20 was found in 59/2790 patients with successful karyotypes entered to the Leukaemia Research Fund/UK Cancer Cytogenetics Group Karyotype Database in ALL (LRF/UKCCG Karyotype Database).
|
10673740 |
2000 |
|
Adult Acute Lymphocytic Leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Monosomy 20 was found in 59/2790 patients with successful karyotypes entered to the Leukaemia Research Fund/UK Cancer Cytogenetics Group Karyotype Database in ALL (LRF/UKCCG Karyotype Database).
|
10673740 |
2000 |
|
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Here we identify the transcriptional repressor Pokemon (encoded by the Zbtb7 gene) as a critical factor in oncogenesis.
|
15662416 |
2005 |
|
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Consequently, dysfunction of vertebrate POZ-ZF proteins, such as promyelocytic leukemia zinc finger (PLZF), B cell lymphoma 6 (Bcl-6), hypermethylated in cancer 1 (HIC-1), Kaiso, ZBTB7 and Fanconi anemia zinc finger (FAZF), has been linked directly or indirectly to tumorigenesis and developmental disorders.
|
16996269 |
2006 |
|
Developmental Disabilities
|
0.010 |
Biomarker
|
group |
BEFREE |
Consequently, dysfunction of vertebrate POZ-ZF proteins, such as promyelocytic leukemia zinc finger (PLZF), B cell lymphoma 6 (Bcl-6), hypermethylated in cancer 1 (HIC-1), Kaiso, ZBTB7 and Fanconi anemia zinc finger (FAZF), has been linked directly or indirectly to tumorigenesis and developmental disorders.
|
16996269 |
2006 |
|
Fanconi Anemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Consequently, dysfunction of vertebrate POZ-ZF proteins, such as promyelocytic leukemia zinc finger (PLZF), B cell lymphoma 6 (Bcl-6), hypermethylated in cancer 1 (HIC-1), Kaiso, ZBTB7 and Fanconi anemia zinc finger (FAZF), has been linked directly or indirectly to tumorigenesis and developmental disorders.
|
16996269 |
2006 |
|
FANCONI ANEMIA, COMPLEMENTATION GROUP A (disorder)
|
0.010 |
Biomarker
|
disease |
BEFREE |
Consequently, dysfunction of vertebrate POZ-ZF proteins, such as promyelocytic leukemia zinc finger (PLZF), B cell lymphoma 6 (Bcl-6), hypermethylated in cancer 1 (HIC-1), Kaiso, ZBTB7 and Fanconi anemia zinc finger (FAZF), has been linked directly or indirectly to tumorigenesis and developmental disorders.
|
16996269 |
2006 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In conclusion, regardless of the pathway followed, the distinct expression of ZBTB7A in cancerous areas and the association with proliferation and tumour size pinpoints a role for this novel cell cycle regulator in the pathogenesis of lung cancer.
|
17907153 |
2007 |
|
Non-Small Cell Lung Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Gene amplification (two- to five-fold) was found in 27.7% of the cases, denoting its significance as a mechanism driving ZBTB7A overproduction in NSCLCs.
|
17907153 |
2007 |
|
Carcinoma
|
0.020 |
AlteredExpression
|
group |
BEFREE |
In the remaining non-amplified group of carcinomas, analysis of the mRNA and protein expression patterns suggested that deregulation at the transcriptional and post-translational level accounts for ZBTB7A overexpression.
|
17907153 |
2007 |
|
Lymphoma
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Although ZBTB7A expression has been found to be increased in various types of lymphoma, there are no reports dealing with its expression in solid tumours.
|
17907153 |
2007 |
|
Malignant neoplasm of lung
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, regardless of the pathway followed, the distinct expression of ZBTB7A in cancerous areas and the association with proliferation and tumour size pinpoints a role for this novel cell cycle regulator in the pathogenesis of lung cancer.
|
17907153 |
2007 |
|
Carcinoma of lung
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, regardless of the pathway followed, the distinct expression of ZBTB7A in cancerous areas and the association with proliferation and tumour size pinpoints a role for this novel cell cycle regulator in the pathogenesis of lung cancer.
|
17907153 |
2007 |
|
Primary malignant neoplasm of lung
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, regardless of the pathway followed, the distinct expression of ZBTB7A in cancerous areas and the association with proliferation and tumour size pinpoints a role for this novel cell cycle regulator in the pathogenesis of lung cancer.
|
17907153 |
2007 |
|
Adult Lymphoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Although ZBTB7A expression has been found to be increased in various types of lymphoma, there are no reports dealing with its expression in solid tumours.
|
17907153 |
2007 |
|
Childhood Lymphoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Although ZBTB7A expression has been found to be increased in various types of lymphoma, there are no reports dealing with its expression in solid tumours.
|
17907153 |
2007 |
|
Non-Small Cell Lung Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Moreover, a prognostic analysis was carried out based upon the immunohistochemical (IHC) detection of the expression of Pokemon gene in archival tumor specimens (5 years ago) of 62 cases of NSCLC.
|
18364119 |
2008 |
|
Lung Neoplasms
|
0.010 |
Biomarker
|
group |
LHGDN |
Overexpression of Pokemon in non-small cell lung cancer and foreshowing tumor biological behavior as well as clinical results.
|
18550205 |
2008 |